

A Phase 1B/2 pan-tumor, open-label study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXD) in subjects with recurrent or metastatic solid tumors (IDeate-Pantumor02)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- disease progression on or after the previous standard-of-care regimen for advanced/metastatic cancer - unable to do strenuous activity but able to walk and do work of a sedentary nature, e.g., light house work, office work - additional criteria required based on the type of cancer (pancreatic, breast, bladder, etc.) - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- prior treatment with orlotamab, enoblituzumab, or other B7-homologue 3 (B7-H3)-targeted agents, including I-DXd - clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms.

Conditions & Interventions

Conditions:

Cancer

Keywords:

Cancer, Recurrent or Metastatic Solid Tumors

More Information

Description: The purpose of this study is to learn more about an investigational drug called ifinatamab deruxtecan (I-DXd; DS-7300). It is being studied to see if it is safe, and if cancer improves while taking it. I-DXd is a type of drug called an antibody drug conjugate (ADC). ADCs are made to attach to tumor cells to deliver chemotherapy directly to tumor cells while sparing healthy cells.

Study Contact: Deanna Teoh - dkteoh@umn.edu

Principal Investigator: Deanna Teoh

Phase: PHASE2

IRB

Number: STUDY00022970

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.